United States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Press/Media

Period7 Mar 2022

Media coverage

2

Media coverage

  • TitleUnited States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
    Media name/outletTendersInfo – News
    Country/TerritoryIndia
    Date7/03/22
    PersonsSundar Jagannath
  • TitleUnited States : U.S. FDA Approves CARVYKTI (ciltacabtagene autoleucel), Janssens First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
    Media name/outletMena Report
    Country/TerritoryUnited Kingdom
    Date7/03/22
    PersonsSundar Jagannath